Cargando…

Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut)

PURPOSE: The incidence of DNMT3A mutations in acute myeloid leukemia (AML) is quite high and often confers a poorer prognosis. Another common gene involved in AML is IDH1/2. However, the influence of IDH1/2 mutations on outcomes in DNMT3A-mutated patients remains unknown. This study aims to determin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xinpei, Shi, Jinlong, Zhang, Jilei, Yang, Xinrui, Zhang, Gaoqi, Yang, Siyuan, Wang, Jing, Ke, Xiaoyan, Fu, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084071/ https://www.ncbi.nlm.nih.gov/pubmed/30122995 http://dx.doi.org/10.2147/CMAR.S157632

Ejemplares similares

Biological and clinical influences of NPM1 in acute myeloid leukemia patients with DNMT3A mutations
por: Yang, Xinrui, et al.
Publicado: (2018)

ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
por: Yang, Xinrui, et al.
Publicado: (2019)

High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
por: Zhang, Gaoqi, et al.
Publicado: (2019)

High Expression Levels of ACTN1 and ACTN3 Indicate Unfavorable Prognosis in Acute Myeloid Leukemia
por: Yang, Xinrui, et al.
Publicado: (2019)

Sphingolipid Pathway as a Source of Vulnerability in IDH1(mut) Glioma
por: Dowdy, Tyrone, et al.
Publicado: (2020)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Expression and prognosis analysis of DNMT family in acute myeloid leukemia
por: Zhang, Ting-Juan, et al.
Publicado: (2020)

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia
por: Berenstein, Rimma, et al.
Publicado: (2014)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3A(mut)NPM1(mut) AMLs
por: Donato, Elisa, et al.
Publicado: (2022)

IDH1/2 mutations in acute myeloid leukemia
por: Byun, Ja Min, et al.
Publicado: (2022)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

ACT-5 Prognosis of IDH-mut lower-grade gliomas in Hokkaido University Hospital
por: Yamaguchi, Shigeru, et al.
Publicado: (2021)

Characteristics of DNMT3A mutations in acute myeloid leukemia
por: Park, Dong Jin, et al.
Publicado: (2020)

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
por: Debarri, Houria, et al.
Publicado: (2015)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Mutation Analysis of Isocitrate Dehydrogenase (IDH1/2) and DNA Methyltransferase 3A (DNMT3A) in Thai Patients with Newly Diagnosed Acute Myeloid Leukemia
por: Sirirat, Tanasan, et al.
Publicado: (2017)

The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation
por: Bhogal, Balpreet, et al.
Publicado: (2022)

DNMT3A co-mutation in an IDH1-mutant glioblastoma
por: Fomchenko, Elena I., et al.
Publicado: (2019)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia
por: Aref, Salah, et al.
Publicado: (2022)

Characterization of FLT3-ITD(mut) acute myeloid leukemia: molecular profiling of leukemic precursor cells
por: Travaglini, Serena, et al.
Publicado: (2020)

A case report of complete remission of acute myeloid leukemia combined with DNMT3A, FLT3-TKD, and IDH2 gene mutations and active pulmonary tuberculosis treated with homeharringtonine + venetoclax + azacytidine
por: Ji, Lin, et al.
Publicado: (2023)

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia
por: Jost, E, et al.
Publicado: (2014)

DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil
por: Pezzi, Annelise, et al.
Publicado: (2012)

Case report: biallelic DNMT3A mutations in acute myeloid leukemia
por: Cumbo, Cosimo, et al.
Publicado: (2023)

The acute myeloid leukemia variant DNMT3A Arg882His is a DNMT3B-like enzyme
por: Norvil, Allison B, et al.
Publicado: (2020)

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia
por: Niederwieser, Christian, et al.
Publicado: (2014)

Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1(mut)) for the Treatment of NPM1(mut)-Acute Myeloid Leukemia
por: De Cicco, Marica, et al.
Publicado: (2023)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h4o8uag01mf4n9120uosbu2aes